Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Active not recruiting 3

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 1Endocrine 1

Conditions

Neoplasm Metastasis 36Leukemia, Myeloid, Acute 32Multiple Myeloma 27Lymphoma 23Breast Neoplasms 18Prostatic Neoplasms 17Pancreatic Neoplasms 17Colorectal Neoplasms 17Lymphoma, Large B-Cell, Diffuse 15Burkitt Lymphoma 15Myelodysplastic Syndromes 14Leukemia, Lymphocytic, Chronic, B-Cell 14Triple Negative Breast Neoplasms 12Ovarian Neoplasms 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Melanoma 11Lung Neoplasms 11Sarcoma 10Lymphoma, T-Cell 9Glioma 9Carcinoma, Non-Small-Cell Lung 9Neuroblastoma 8Neoplasms 8Fallopian Tube Neoplasms 8Carcinoma, Renal Cell 8Squamous Cell Carcinoma of Head and Neck 7Lymphoma, Non-Hodgkin 7Lymphoma, Follicular 7Leukemia, Biphenotypic, Acute 7Endometrial Neoplasms 7

Interventions

Etoposide 30Carboplatin 29atezolizumab 17durvalumab 16Cisplatin 14Topotecan 11Specimen Handling 9PM 01183 9Magnetic Resonance Spectroscopy 7pembrolizumab 6olaparib 5berzosertib 4anlotinib 4Radiotherapy 4Nivolumab 4Irinotecan 4Drug Therapy 4tremelimumab 3toripalimab 3tislelizumab 3Paclitaxel 3Injections 3Docetaxel 3Biopsy 3Bevacizumab 3AMG 757 3sacituzumab govitecan 2monalizumab 2cabozantinib 2Temozolomide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × Biopsy × 90 days × Clear all
NCT04514497 2026-06-02

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
29 enrolled 25 charts
EndocrineGastrointestinalThoracic

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT03896503 2026-06-01

Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs

National Cancer Institute (NCI)

Phase 2 Active not recruiting
104 enrolled 22 charts
Thoracic

Small Cell Lung Carcinoma

NCT05353439 2026-05-13

Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
18 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡